Related Experiment Video
Updated: Mar 13, 2026

Generating Transposon Insertion Libraries in Gram-Negative Bacteria for High-Throughput Sequencing
Published on: July 7, 2020
Updates in the Management of Cephalosporin-Resistant Gram-Negative Bacteria
Andre Arizpe1, Kelly R Reveles1,2, Shrina D Patel3
1College of Pharmacy, The University of Texas at Austin, Austin, TX, USA.
Abstract:
Resistance to cephalosporins is now common among Gram-negative bacterial infections, including those caused by the Enterobacteriaceae and Pseudomonas aeruginosa, posing a major threat to public health. As resistance to the traditional drugs of choice for these infections, carbapenems, has also become increasingly common, interest in cefepime and piperacillin-tazobactam as carbapenem-sparing alternatives has increased. Additionally, the availability of the novel β-lactam-β-lactamase inhibitor combinations ceftolozane-tazobactam and ceftazidime-avibactam has added to the antimicrobial armamentarium available to treat these multidrug-resistant infections. Here, we review the recent literature on the use of carbapenem-sparing alternatives and highlight the potential utility of novel antimicrobials.
Insights
Antimicrobial resistance to cephalosporins and carbapenems is rising in Gram-negative infections. Novel agents and carbapenem-sparing options like cefepime offer alternatives for multidrug-resistant bacteria.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Increasing resistance to cephalosporins and carbapenems in Gram-negative bacterial infections (Enterobacteriaceae, Pseudomonas aeruginosa) is a significant public health concern.
- Rising carbapenem resistance necessitates exploring alternative treatment strategies to preserve carbapenem efficacy.
Approach:
- Review of recent literature on carbapenem-sparing antimicrobial agents.
- Evaluation of novel beta-lactam/beta-lactamase inhibitor combinations for treating multidrug-resistant Gram-negative infections.
Key Points:
- Cefepime and piperacillin-tazobactam are increasingly used as carbapenem-sparing alternatives.
- Novel agents like ceftolozane-tazobactam and ceftazidime-avibactam expand treatment options.
- Effective management of multidrug-resistant Gram-negative infections requires strategic antimicrobial selection.
Conclusions:
- Carbapenem-sparing alternatives and novel antimicrobial combinations are crucial in combating rising resistance.
- Further research and clinical application of these agents are vital for preserving treatment efficacy against challenging Gram-negative pathogens.
More Related Videos
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Development of Antibiotic Resistance
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Urine Studies II: Urine Culture and Sensitivity Test
Biological Methods for Microbial Control

